Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .
Sixty - two patients with a heparin - induced thrombocytopenia are reported .
Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .
Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient 's plasma when heparin is added .
Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .
The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .
Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .
If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient 's plasma , is indicated .
Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .